"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • Resources
  • FDA Approvals
  • FDA GRANTED REGULAR APPROVALS TO DABRAFENIB AND TRAMETINIB (TAFINLAR AND MEKINIST, NOVARTIS) ADMINISTERED IN COMBINATION FOR PATIENTS WITH NSCLC

FDA GRANTED REGULAR APPROVALS TO DABRAFENIB AND TRAMETINIB (TAFINLAR AND MEKINIST, NOVARTIS) ADMINISTERED IN COMBINATION FOR PATIENTS WITH NSCLC

23 Jun 2017 9:39 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approvals to dabrafenib and trametinib (Tafinlar and Mekinist, Novartis) administered in combination for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software